The non-covalent binding of ethidium monoazide to nucleic acids is entirely analogous to that of ethidium (binding constant ^2-3xl0 5 M) . The ethidium monoazide can be photochemically covalently linked to nucleic acids in high yield, up to 75%, by long wavelength light. The fluorescence of ethidium monoazide and ethidium crosslinked to nucleic acids show the same environmental sensitivity as does the fluorescence of ethidium. These properties of ethidium monoazide indicate its use as a fluorescent photoaffinity label for nucleic acids. Ethidium diazide can be photochemically linked to nucleic acids but appears to have properties substantially different from those of ethidium.
INTRODUCTION
There are a number of drug molecules which are thought to exhibit their biological activity by intercalating between the base pairs of RNA and DNA.
The geometry of many intercalative complexes have been investigated in both the crystal and solution states, 1 " 5 but the correlation between the biological activity and structure of the intercalative complex has remained unclear. Also, the number of base pairs affected by the intercalative binding of a drug to double helical nucleic acids is known in only a few instances. 6 The effect of intercalative drugs on the recognition of nucleic acids by proteins is not well understood. For non-covalently attached drugs the investigation of the effect of drug binding on the biological activity of nucleic acids is inherently difficult, since the drug molecules may move from site to site during the time of a biological assay, making the assignment of the active binding site(s) ambiguous. Furthermore, there may be complications due to the binding of the drugs to the proteins of interest.
One method to at least partially overcome some of these difficulties is to use drug molecules which can be covalently attached to nucleic acids.
Covalently bound drug molecules offer several advantages relative to noncovalently bound drugs. The covalently bound drugs allow selective labeling of the nucleic acid, at least for in vitro experiments. The binding site(s) of covalently bound drugs can be determined by sequencing methods, and long range structural perturbations introduced by covalently bound drugs can be conveniently investigated. In appropriate cases the drug molecule can be used as a probe of protein-nucleic acid interactions if the fluorescence or some other property of the drug exhibits environmental sensitivity. Psoralen and its derivatives are one group of molecules which can be photochemically linked to nucleic acids both in_ vitro and in_ vivo and have been very useful in investigating nucleic acid structures as well as the effect of drugs on the biological activity of nucleic acids. 7 Azide derivatives are another potentially useful class of compounds. Preliminary results with partially purified azide derivatives of ethidium bromide showed that these drugs can be photochemically crosslinked to nucleic acids both in vivo and in vitro and that the covalently attached drug is a frameshift mutant as well as a stimulator of DNA repair synthesis in human lymphocytes. 8 "
10
The purification of the monoazide was subsequently reported by Graves et al., 11 but the details of the photochemical reaction and the nature of the interaction of the monoazd.de and the covalently bound drug with DNA and RNA has not been studied, nor have the fluorescent properties of these compounds been reported.
In the present study, we examined the interaction of the monoazide with RNA and DNA and studied the photochemical and spectroscopic properties of the photochemically linked ethidium. In view of the well known environmental sensitivity of the fluorescence of the parent compound, 12 we also examined the fluorescence of the azide derivatives, both free in solution and bound to DNA and tRNA, and in the photocrosslinked samples. As we shall demonstrate, the monoazide derivative of ethidium binds strongly to both DNA and tRNA, and can be photochemically crosslinked to polynucleotides in yields approaching 75% using long wavelength light. The ethidium monoazide appears to exhibit the same type of binding to nucleic acids as does ethidium, the archetypical intercalating drug. Both the free and crosslinked ethidium monoazide are highly fluorescent and appear to exhibit environmental sensitivity entirely analogous to the fluorescence of ethidium.
EXPERIMENTAL
Calf thymus and salmon sperm DNA were obtained from Worthington Biochemical, E_. coli tRNA from Plenum Scientific and ethidium bromide from Sigma.
All other chemicals were of reagent grade or higher and doubly distilled water was used in all solutions.
Nucleic Acids Research
Ethidium monoazide and ethidium dlazide ( Figure 1 ) were synthesized and purified by the method of Graves et al.
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The azide compounds were characterized by their absorption and NMR spectra which were in excellent agreement with those reported by Graves et al. 1 1 for crystallized samples.
Absorption spectra were obtained with a Beckman Acta CIII spectrometer.-
The absorption spectra of the azide compounds were obtained at low concentration, typically 0.05 mM, as it was observed that the soectra are concentration dependent (>2xlO~'*M) . Fluorescence spectra were obtained using a home built fluorimeter employing a xenon lamp. Samples of ethidium crosslinked to tRNA or ribosomal RNA were digested to mononucleotides with a mixture of pancreatic RNase and T. RNase. The ethanol precipitation procedure was found to be inconvenient for DNA samples due to the difficulty in redissolving the ethanol precipitated DNA.
RESULTS AND DISCUSSION
Absorption spectra. The absorption spectrum of ethidium monoazide has previously been reported and its extinction coefficient determined. 11 The spectrum of ethidium monoazide that we obtained is in excellent agreement with the reported absorption spectrum for crystallized ethidium monoazide. 11 Photolysis of ethidium monoazide induces a shift of the absorption maximum to longer wavelength without appreciable change in the extinction coefficient at the absorption maximum, see Table 1 .
The absorption spectra of both ethidium monoazide and photolysed ethidium monoazide change markedly in the presence of nucleic acid; the wavelength of maximum absorption shifts to longer wavelength by about 40 nm and the extinction coefficient for both drugs decreases as shown in Table 1 .
Similar changes are observed for the absorption spectrum of ethidium upon binding to nucleic acid.
The absorption spectrum of ethidium monoazide photocrosslinked to tRNA or DNA is similar to that of ethidium monoazide non-covalently bound to nucleic acid, as indicated in Table 1 . When a sample of ethidium monoazide photocrosslinked to tRNA is extensively digested with RNases, the absorption maximum shifts to shorter wavelength and the absorption strength increases, as indicated in Table 1 . The relative change in extinction coefficient in going from bound to nucleic acid to free drug (or digested RNA-drug) is the same for ethidium monoazide and photocrosslinked ethidium monoazide. Furthermore, the extinction coefficient of the drug does not appear to change appreciably after photolysis in aqueous solution. These considerations indicate that the extinction coefficient for photocrosslinked ethidium monoazide is about the same as that of the photolysed or unreacted ethidium monoazide, see Table 1 . Yield of Photocrosslinking Reaction. The yield of the photocrosslinking (percent of the initially added drug covalently bound to nucleic acid) was evaluated from the visible absorption of the drug-nucleic acid sample after removal of all of the non-covalently bound drug. The results in Figure 2 show that the yield for crosslinking to DNA is constant (at low levels of drug per nucleic acid) with a value of 75%. With tRNA the maximum yield is about 45% in the absence of magnesium and only about 25% in the presence of Since both the monoazide and the croBslinked ethidium exhibit entirely analogous behavior, it is reasonable to propose that the environmental sensitivity of ethidium monoazide and the crosslinked ethidium is also due to inhibition proton transfer from excited state drug molecules.
Studies with ethidium have shown that the relative fluorescence quantum yield of the drug bound to DNA is constant at low levels of the drug. 15 At high levels of the drug the relative fluorescence quantum yield decreases as the drug is bound both by intercalation and by outside binding. The data in Figure 5A show that ethidium crosslinked to DNA at low drug to base pair Fluorescence decay of ethidium crosslinked to tRNA. The crosslinking was performed in 0.1 M NaCl, 10 njM MgCl 2 and 10 mM cacodylate at pH 7 at a level of 0.5 drug/tRNA. The decay curve was analyzed by the method of moments after the lamp pulse had been deconvoluted. 12 The analysis showed that there are two components to the decay as indicated in the figure. Fingerprinting of the crosslinked ethidium-tRNA will allow unambiguous identification of the binding site.
The effect of ethidium and ethidium monoazide on the viscosity of DNA was examined since it is known that ethidium has a pronounced effect on the viscosity of DNA.
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Only a few measurements were made and these indicated that both ethidium and ethidium monoazide increased the viscosity of DNA solutions by ^35%. 
